Jan. 14, 2025 — A team of researchers has developed a new biomaterial with high potential in in the treatment of bone lesions or minimal residual disease in multiple myeloma patients.

has developed a new biomaterial with high potential in the treatment of bone lesions or minimal residual disease in multiple myeloma patients. The findings showcase a promising approach to bone ...

Patients with multiple myeloma often develop bone lesions resulting in skeletal-related events (SREs), such as spinal cord compression, vertebral collapse, pathologic fractures and bone pain. Bone ...

Myeloma develops due to the accumulation of multiple pathological genetic events ... chain variable region constitute primary genetic lesions. These primary lesions co-operate with secondary ...

The team tackled a critical challenge in treating multiple myeloma -- a blood cancer where malignant plasma cells accumulate in bone marrow, leading to debilitating bone lesions in 80% of patients.

Across all dose levels, the most common adverse events were cytokine release syndrome, neutropenia, taste changes, and nonrash skin events. Grade 3 or 4 adverse events, most commonly hematologic ...

Early treatment with intravenous bisphosphonates at first radiographic evidence of bone lesions in patients with solid tumors or evidence of osteopenia in patients with multiple myeloma can ...